



Innovative Cell and Tissue Technology

Press release
November 30, 2007
Kungsbacka, Sweden

Conversion of warrants

At the first time of conversion of Vitrolife's warrants program 2005/2008, 10,000 warrants have been converted into shares in Vitrolife AB (publ). This means that at November 30, 2007 the number of shares has increased from 19,790,157 to 19,800,157. The quota value is SEK 1 and the share capital has thus increased to SEK 19,800,157.

The subscription period for the warrants program 2005/2008 is up until September 3, 2008. The total number of warrants in the program is 550,000. The issue price is SEK 30.90.

November 30, 2007
Kungsbacka, Sweden

Vitrolife AB (publ)

Queries should be addressed to:

Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 140 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.

Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.